FY2025 · ended Dec 31, 2025 · Revenue $1.73M, +40.0% YoY · Filed Mar 31, 2026
VolitionRx Limited (VNRX) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.7 million and a net loss of $23.4 million. Free cash flow was -$19.8 million. As of Jun 30, 2026 it held $2.8 million in cash and investments and $7.7 million in total debt.
Revenue (TTM)
$2.46M
+86.3% vs year-ago TTM
Net income (TTM)
$-25.64M
-9.9% vs year-ago TTM
Operating cash flow (TTM)
$-19.56M
+8.5% vs year-ago TTM
Free cash flow (TTM)
$-19.58M
+9.6% vs year-ago TTM
EPS (TTM)
$-0.24
Dividend per share
None
Shares outstanding
8.09M
-94.9% vs prior year
Net cash
$-4.95M
as of Jun 30, 2026
Operating margin
-791.2%
FY 2026
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- VNRX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Henderson, NV
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 93314
- Former names
- VOLITIONRX LTD (until Oct 27, 2026); STANDARD CAPITAL CORP (until Sep 29, 2011)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.7M | $1.2M | $775,302 | $306,392 | $90,035 |
| Operating income | -$21.7M | -$27.0M | -$36.0M | -$31.8M | -$28.3M |
| Net income | -$23.4M | -$27.0M | -$35.7M | -$30.6M | -$27.0M |
| Diluted EPS | — | -$0.31 | — | — | — |
| Operating cash flow | -$19.7M | -$25.9M | -$18.1M | -$15.3M | -$20.9M |
| Free cash flow | -$19.8M | -$26.2M | -$19.1M | -$16.8M | -$21.8M |
| Total assets | $6.9M | $9.4M | $28.0M | $18.3M | $27.5M |
| Total liabilities | $42.5M | $35.5M | $36.7M | $21.4M | $9.8M |
| Stockholders' equity | -$34.2M | -$24.9M | -$7.8M | -$2.6M | $17.7M |
| Cash and investments | $1.1M | $3.3M | $20.7M | $10.9M | $20.6M |
| Total debt | $7.6M | $5.8M | $5.9M | $5.0M | $4.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Other events
|
Oct 27, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Sep 25, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Sep 15, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 11, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 2, 2026 | Sep 2, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Sep 2, 2026 | Aug 27, 2026 |
All 1004 VolitionRx Limited SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.